Javascript must be enabled to continue!
Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas
View through CrossRef
Canine and feline fibrosarcomas are malignant tumors of mesenchymal origin showing histological, molecular, and clinical structures similar to their human equivalent. In human medicine, cellular myelocytomatosis (c-Myc) has already been proposed as a vital gene that regulates aggressive cell growth and is a predictive marker and possible therapeutic target in fibrosarcomas. The goal of this study was to evaluate c-Myc expression in canine and feline fibrosarcomas by gene and protein analyses and correlate its expression to the histological grading system of the examined cancers. Nineteen archival formalin-fixed and paraffin-embedded canine and feline sarcoma samples were recruited. Sixteen of them were determined to be canine and feline fibrosarcomas. The samples consisted of eight cutaneous samples, four eyelid samples, three oral mucosa samples, and one vulva sample. Histopathological examinations were performed to estimate histological type, differentiation, cellularity, and mitotic count. On each sample, immunohistochemical assessment and mRNA expression were performed using an anti-c-Myc antibody and a c-Myc primer. The differences in the immunoreactivity staining values and the relative folds of the c-Myc mRNAs were categorized using already recognized grading criteria and a statistical analysis was performed. Among all the tested canine and feline fibrosarcomas, 75% of the grade II fibrosarcoma cases and all of the grade III fibrosarcoma cases were positive for the c-Myc protein. Furthermore, the relative values of the c-Myc gene were up-regulated in grade III compare to grade I and II fibrosarcomas. The results demonstrated that c-Myc expression was significantly higher in grade III than in grade II and I (p ≤ 0.05) fibrosarcomas regarding protein and gene levels. In summary, this work provides evidence for the high expression of c-Myc in canine and feline fibrosarcomas and proposes a supposed relationship with poor prognoses as determined by grading systems.
Title: Gene Expression and Immunohistochemical Analyses of c-Myc in Canine and Feline Soft Tissue Fibrosarcomas
Description:
Canine and feline fibrosarcomas are malignant tumors of mesenchymal origin showing histological, molecular, and clinical structures similar to their human equivalent.
In human medicine, cellular myelocytomatosis (c-Myc) has already been proposed as a vital gene that regulates aggressive cell growth and is a predictive marker and possible therapeutic target in fibrosarcomas.
The goal of this study was to evaluate c-Myc expression in canine and feline fibrosarcomas by gene and protein analyses and correlate its expression to the histological grading system of the examined cancers.
Nineteen archival formalin-fixed and paraffin-embedded canine and feline sarcoma samples were recruited.
Sixteen of them were determined to be canine and feline fibrosarcomas.
The samples consisted of eight cutaneous samples, four eyelid samples, three oral mucosa samples, and one vulva sample.
Histopathological examinations were performed to estimate histological type, differentiation, cellularity, and mitotic count.
On each sample, immunohistochemical assessment and mRNA expression were performed using an anti-c-Myc antibody and a c-Myc primer.
The differences in the immunoreactivity staining values and the relative folds of the c-Myc mRNAs were categorized using already recognized grading criteria and a statistical analysis was performed.
Among all the tested canine and feline fibrosarcomas, 75% of the grade II fibrosarcoma cases and all of the grade III fibrosarcoma cases were positive for the c-Myc protein.
Furthermore, the relative values of the c-Myc gene were up-regulated in grade III compare to grade I and II fibrosarcomas.
The results demonstrated that c-Myc expression was significantly higher in grade III than in grade II and I (p ≤ 0.
05) fibrosarcomas regarding protein and gene levels.
In summary, this work provides evidence for the high expression of c-Myc in canine and feline fibrosarcomas and proposes a supposed relationship with poor prognoses as determined by grading systems.
Related Results
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract
Small cell lung cancer and large cell neuroendocrine carcinoma are classified as high-grade neuroendocrine tumors of the lung, representing extremely agg...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Abstract
Background: The diagnosis of Burkitt lymphoma (BL) is usually based on histopathology (HP), immunohistochemistry (IHC), fluorescence in situ hybridization (...
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Abstract
Background and significance. Stemness in acute myeloid leukemia (AML) is determined by a clonal hierarchy with ...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...
Abstract 1457: NELFE regulates chromatin accessibility to affect MYC induced transcription
Abstract 1457: NELFE regulates chromatin accessibility to affect MYC induced transcription
Abstract
Liver cancer incidence rates have more than tripled in the last 40 years and is projected to increase more than 40% in the next decade. Although progress ha...
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Abstract
MYC activation and dysregulation is a powerful oncogenic driver in multiple cancers, including diffuse large B cell lymphoma (DLBCL). There is a known corre...

